Liraglutide dans le traitement de l’obésité : une prise en charge multidisciplinaire [Liraglutide in the treatment of obesity : a multidisciplinary approach]
Fiche du document
23 mars 2022
- doi: 10.53738/REVMED.2022.18.774.516
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2022.18.774.516
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/35343119
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_43EB9FD178F28
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
TherapyCiter ce document
S. Nest et al., « Liraglutide dans le traitement de l’obésité : une prise en charge multidisciplinaire [Liraglutide in the treatment of obesity : a multidisciplinary approach] », Serveur académique Lausannois, ID : 10.53738/REVMED.2022.18.774.516
Métriques
Partage / Export
Résumé
Liraglutide, which has been prescribed for several years for the treatment of type 2 diabetes, is now proposed for the management of patients with BMI between 28 and 35 kg/m 2 in the presence of metabolic comorbidity or BMI ≥ 35 kg/m 2 . Its reimbursement by the health insurance is conditioned on weight loss results and time limited. Careful preparation of the patient and his commitment to lifestyle changes are essential for the success and good tolerance of the treatment. The introduction of this treatment requires a multidisciplinary follow-up to ensure optimal results. The place of liraglutide in the pharmacopeia of obesity, a chronic disease that requires long-term treatment, should be clarified.